Today: 7 February 2026
Subscribe
Browse Category

NYSE:BMY News 28 December 2025 - 5 February 2026

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft shares fell 1.1% to $454.52 in after-hours trading Tuesday, tracking a broad tech selloff as tariff concerns rattled markets. Bristol Myers Squibb announced a partnership to use Microsoft’s AI radiology tools for early lung cancer detection. Investors are awaiting Microsoft’s fiscal Q2 earnings on Jan. 28 for updates on cloud and AI growth. The S&P 500 closed down 2.04%, Nasdaq off 2.38%.
20 January 2026
···
Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia dropped 3.4% to $179.83, dragging AI stocks lower as U.S. markets fell on tariff threats from President Trump over Greenland. The Nasdaq lost 1.6% and S&P 500 slid 1.3% in early trading. Morgan Stanley downgraded IT hardware, citing weak demand and high costs. Microsoft, Broadcom, and Palantir also declined, while AMD rose 1.3%.
20 January 2026
············
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

New York, Jan 12, 2026, 07:52 EST — Premarket Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday’s premarket session. (Investing.com) The bid emerged amid a volatile morning for growth stocks, with Nasdaq 100 futures slipping close to 1% as investors digested fresh doubts over the Federal Reserve’s independence and prepared for earnings season to begin. (Reuters) Tempus projected full-year 2025 revenue around $1.27 billion in an SEC filing, marking an 83% jump from the previous year. That includes roughly 30% organic growth without Ambry. Diagnostics revenue hit about $955 million, soaring 111%, while data and applications brought in
12 January 2026
······
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

New York, January 7, 2026, 20:54 (EST) — Market closed Bristol Myers Squibb shares rose 4.2% to $56.72 on Wednesday after UBS upgraded the drugmaker to buy and lifted its price target to $65 from $46. TipRanks The call matters now because big drugmakers are trying to convince investors they can bridge the next few years of patent losses without giving up growth later. Bristol Myers has been a litmus test for that trade: steady cash flows, but an earnings gap investors do not want to underwrite blindly. UBS analyst Michael Yee said the stock’s “risk/reward ratio” is “skewed… to
8 January 2026
·
Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

NEW YORK, Jan 3, 2026, 17:25 ET — Market closed Bristol-Myers Squibb shares ended down 0.9% at $53.46 on Friday, after the company confirmed it will present at J.P. Morgan’s annual healthcare conference on Jan. 12. JPMorgan Chase The San Francisco conference is the sector’s first major investor gathering of the year, often setting the tone for how traders price pipelines, deal appetite and 2026 outlooks. JPMorgan Chase For Bristol-Myers, the timing is sensitive. Investors are balancing a just-passed dividend cutoff with a Feb. 5 earnings report and a Medicaid pricing change for Eliquis that took effect on Jan. 1.
3 January 2026
··
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly. Cytokinetics has said Myqorzo is expected
1 January 2026
····
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

NEW YORK, December 30, 2025, 23:30 ET — Market closed Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors The modest gain came as Wall Street drifted lower in holiday-thinned trade. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, as investors repositioned after a tech-led run; the S&P 500 slipped 0.14% and the Nasdaq fell 0.23%. Reuters Why it matters now:
31 December 2025
··
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

NEW YORK, December 29, 2025, 14:15 ET — Regular session Bristol Myers Squibb shares fell on Monday, with the drugmaker lagging a slightly weaker U.S. stock market in holiday-thinned trading. The stock was down 0.7% at $54.27 in afternoon trade. The move matters now because the final week of the year often brings abrupt swings on light volume, even when company-specific headlines are scarce. Bristol Myers is also approaching two calendar catalysts that can influence positioning: its next dividend record date and its next earnings report. U.S. stocks eased from record highs at the start of a holiday-shortened week, and
29 December 2025
···
Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

NEW YORK, December 28, 2025, 23:31 ET — Market closed Bristol Myers Squibb shares ended Friday slightly lower at $54.64, as the U.S. market headed into the year’s final trading days with few fresh company-specific catalysts. Bristol Myers Squibb That matters now because thin year-end liquidity — lower trading volume around the holidays — can amplify day-to-day swings, even when headlines are scarce. Investors are also adjusting portfolios into 2026, a process that can trigger abrupt sector rotations. Reuters For Bristol Myers, a large-cap drugmaker often traded as a defensive holding, the near-term tape is being shaped more by rates
29 December 2025
·
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 2:53 PM ET, Market closed Bristol Myers Squibb Company (NYSE: BMY) enters the final trading stretch of 2025 with investors balancing a defensive “big pharma” profile and above-market income appeal against policy headlines and the long-running question hanging over the name: how quickly can new launches and pipeline catalysts offset upcoming loss-of-exclusivity (LOE) pressure in key franchises? With U.S. equity markets closed for the weekend, BMY’s most recent official print is Friday’s regular-session close at $54.64, down 0.13% on the day. The stock traded between $54.38 and $55.04 with volume of 9.57 million shares, sitting
28 December 2025
·
1 2 3

Stock Market Today

Lumentum stock hits a record close — Citi raises target, insider filing lands ahead of Monday

Lumentum stock hits a record close — Citi raises target, insider filing lands ahead of Monday

7 February 2026
New York, Feb 7, 2026, 06:03 (EST) — Market closed. Lumentum Holdings Inc shares ended Friday at a record $551.99, up $47.14, or 9.3%, after briefly trading as high as $558.22. U.S. markets are shut on Saturday. The late-week jump kept the optics maker in view as investors track a swelling wave of spending on artificial intelligence infrastructure. Alphabet, Microsoft, Amazon and Meta said they expect more than $630 billion of combined spending in 2026, Reuters reported. (Reuters) Amazon alone projected $200 billion of capital spending this year, a figure that has sharpened the debate over payback but also underlined
Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

7 February 2026
Lucid Group shares jumped 14% to $10.86 at Friday’s close, recovering from an 8% drop the previous day. The move followed a broad Wall Street rally that lifted high-volatility stocks. Lucid reported fourth-quarter deliveries of 5,345 vehicles and full-year deliveries of 15,841. Investors await Lucid’s Feb. 24 results for updates on cash and demand.
Go toTop